The CUROSURF Experience Program

A smooth process for evaluating CUROSURF in your NICU

The CUROSURF Experience Program is a multifaceted partnership designed to help you seamlessly integrate CUROSURF into your NICU. With the CUROSURF Experience Program, your NICU will gain:

  • Valuable hands-on experience with CUROSURF. Before you switch surfactants, evaluate CUROSURF with your protocols to experience the difference fast RDS success makes.
  • Dedicated staff training and service. For seamless evaluation in your NICU, we will provide a dedicated in-service team to train your staff in storage and usage, and to match CUROSURF with your protocols.
  • Special evaluation price. A low-cost way to experience CUROSURF during the evaluation period.
  • Service after evaluation. You will receive ongoing support throughout the process of transitioning to CUROSURF, as well as continued education and support for your staff and timely updates on new protocols and product information.

Getting started with the CUROSURF Experience Program is simple: Simply fill out an electronic request information form or contact your Cornerstone sales representative.

Is my hospital eligible to receive the benefits of the CUROSURF Experience Program? Hospitals will be eligible if they have not purchased or used CUROSURF in the previous 12 months. The special evaluation price is valid for 30 days after you begin receiving CUROSURF.

Request Information Form

Explore the unique benefits of CUROSURF, such as efficient administration, a rapid onset of action, sustained results with fewer doses, and success with less invasive ventilation, for fast RDS success.
Learn More

Clinical studies have not established that fewer doses result in superior safety or efficacy based on clinically relevant end points.

Indication

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the treatment (rescue) of respiratory distress syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Important Safety Information

CUROSURF is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified in response to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHEAL TUBE BLOCKAGE, AND OXYGEN DESATURATION. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Click here for full prescribing information

This site is intended for United States residents only.